KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Finished Goods: 2011-2012

Historic Finished Goods for Vertex Pharmaceuticals (VRTX) over the last 1 years, with Sep 2012 value amounting to $23.3 million.

  • Vertex Pharmaceuticals' Finished Goods rose 94.18% to $23.3 million in Q3 2012 from the same period last year, while for Sep 2012 it was $23.3 million, marking a year-over-year increase of 94.18%. This contributed to the annual value of $33.2 million for FY2011, which is N/A change from last year.
  • As of Q3 2012, Vertex Pharmaceuticals' Finished Goods stood at $23.3 million, which was down 0.81% from $23.5 million recorded in Q2 2012.
  • In the past 5 years, Vertex Pharmaceuticals' Finished Goods ranged from a high of $33.2 million in Q4 2011 and a low of $12.0 million during Q3 2011.
  • Over the past 2 years, Vertex Pharmaceuticals' median Finished Goods value was $23.5 million (recorded in 2012), while the average stood at $23.7 million.
  • Data for Vertex Pharmaceuticals' Finished Goods shows a peak YoY soared of 94.18% (in 2012) over the last 5 years.
  • Vertex Pharmaceuticals' Finished Goods (Quarterly) stood at $33.2 million in 2011, then skyrocketed by 94.18% to $23.3 million in 2012.
  • Its Finished Goods was $23.3 million in Q3 2012, compared to $23.5 million in Q2 2012 and $26.3 million in Q1 2012.